John E. (Jack) Bailey Jr. is CEO & President at G1 Therapeutics, Inc. (GTHX). They have made 7 open-market trades across 1 company since 2020, most recently 2024-09-18.
CIK 0001806147
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $102K since 2020, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GTHX | 196,287 | $1.4M |
Shares reported on the most recent Form 4, priced at the 2024-09-18 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GTHX | SELL | 2024-07-05 | 2024-07-08 | $2.51 | $19K | +42.2% | +175.8% | N/A |
| GTHX | SELL | 2024-05-13 | 2024-05-15 | $4.79 | $357K | -26.2% | -39.7% | +53.6% |
| GTHX | SELL | 2024-01-03 | 2024-01-08 | $3.12 | $36K | +1.8% | +43.8% | +42.0% |
| GTHX | SELL | 2024-01-02 | 2024-01-02 | $3.27 | $216K | +4.6% | +45.8% | +48.7% |
| GTHX | SELL · 10b5-1 | 2023-07-05 | 2023-07-07 | $2.45 | $7K | +10.8% | -15.8% | -47.3% |
| GTHX | SELL | 2023-01-03 | 2023-01-05 | $5.83 | $406K | +24.8% | +45.1% | -51.4% |
| GTHX | SELL | 2022-01-03 | 2022-01-05 | $10.41 | $710K | -10.7% | -4.2% | -21.3% |
| GTHX | BUY | 2020-11-10 | 2020-11-13 | $12.80 | $102K | +2.2% | +46.8% | +144.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.